Home › Compare › GSGTF vs MCD

GSGTF vs MCD: Dividend Comparison 2026

GSGTF yields 1052.08% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GSGTF wins by $29376466.47M in total portfolio value
10 years
GSGTF
GSGTF
● Live price
1052.08%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29376466.55M
Annual income
$24,748,961,707,406.69
Full GSGTF calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — GSGTF vs MCD

📍 GSGTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGSGTFMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GSGTF + MCD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GSGTF pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GSGTF
Annual income on $10K today (after 15% tax)
$89,426.62/yr
After 10yr DRIP, annual income (after tax)
$21,036,617,451,295.69/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, GSGTF beats the other by $21,036,617,429,002.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GSGTF + MCD for your $10,000?

GSGTF: 50%MCD: 50%
100% MCD50/50100% GSGTF
Portfolio after 10yr
$14688233.31M
Annual income
$12,374,480,866,817.20/yr
Blended yield
84.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

GSGTF
No analyst data
Altman Z
-9.7
Piotroski
2/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GSGTF buys
0
MCD buys
0
No recent congressional trades found for GSGTF or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGSGTFMCD
Forward yield1052.08% ✓2.35%
Annual dividend / share$2.00$7.26 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3% ✓
Portfolio after 10y$29376466.55M ✓$78.5K
Annual income after 10y$24,748,961,707,406.69 ✓$26,227.70
Total dividends collected$29025351.72M ✓$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: GSGTF vs MCD ($10,000, DRIP)

YearGSGTF PortfolioGSGTF Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$115,908$105,207.79$10,815$334.85+$105.1K → GSGTF
2$1,263,685$1,139,663.68$11,826$491.71+$1.25M → GSGTF
3$12,964,467$11,612,324.37$13,123$730.06+$12.95M → GSGTF
4$125,211,982$111,340,001.64$14,853$1,100.07+$125.20M → GSGTF
5$1,138,959,685$1,004,982,865.01$17,257$1,690.61+$1138.94M → GSGTF
6$9,762,216,739$8,543,529,875.74$20,752$2,667.01+$9762.20M → GSGTF
7$78,882,996,544$68,437,424,632.64$26,103$4,354.83+$78882.97M → GSGTF
8$601,231,379,017$516,826,572,714.96$34,794$7,437.78+$601231.34M → GSGTF
9$4,324,770,879,470$3,681,453,303,922.24$49,926$13,461.60+$4324770.83M → GSGTF
10$29,376,466,548,439$24,748,961,707,406.69$78,550$26,227.70+$29376466.47M → GSGTF

GSGTF vs MCD: Complete Analysis 2026

GSGTF — Stock

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

Full GSGTF Calculator →

MCD — Consumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this GSGTF vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GSGTF vs SCHDGSGTF vs JEPIGSGTF vs OGSGTF vs KOGSGTF vs MAINGSGTF vs YUMGSGTF vs QSRGSGTF vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.